Enhanced Biomarker Test Aids Clinicians With Difficult to Treat Psychiatric Disorders

Share Article

The Genecept™ Assay includes three additional genes, an expanded report, and an upgraded platform

Today, Genomind announced enhancements to its Genecept™ Assay, a proprietary biomarker test and analytic report, which helps inform treatment options in neuropsychiatry. The enhancements include adding three new genes to its panel, a redesigned report, and an upgraded technical platform.

Clinicians use the Genecept Assay to help design optimized treatment plans for their difficult to treat patients, based on the individual’s genetic makeup. The Assay can help inform treatment plans for depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. The new genes include two additional pharmacodynamic genes (5HT2C and ANK3) and one pharmacokinetic gene (CYP3A4). Pharmacokinetic genes indicate how the body will react to certain drugs, while pharmacodynamic genes indicate how certain drugs affect the body. The additional genes in the panel expand the medication list for clinical interpretation, and this expanded list also helps avoid drug-drug interactions for patients.

“Genomind never stops innovating.” says Dr. Jay Lombard, chief scientific officer and co-founder. “The value of the Genecept assay is in its relevance and ability to be integrated in clinical practice.”

In addition to the new genes, the Genecept Assay Report has been expanded and redesigned to give clinicians an executive summary of the information provided. It now includes a more specific indication of gene variations, a comprehensive summary of published scientific literature related to each gene on the panel, and delineated therapies related to each genotype result.

Other report features will help clinicians more easily compare their patient’s current regimen or intended treatment against clinical data. The reference list now includes highlighted key clinical implications from each study. Genomind also added a list of common substrates, inducers and inhibitors of the cytochrome p450 enzymes analyzed by the Assay, as well as a brief overview of the significance of those inducers and inhibitors.

Finally, Genomind enhanced the Assay for administrative ease of use and performance. The technical platform has been improved, leading to better quality and faster processing of test results.

About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.

About Genomind
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Doreen Korba
Genomind, LLC
215.396.5596
Email >
Visit website